Dergiler / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 2

Gene Therapies for Inherited Retinal Diseases

Sayfa
115–122
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Finally, we discuss trends in gene therapy pricing and approaches in determining the cost effectiveness of single-dose gene therapies for IRDs.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Gene therapy is an emerging therapeutic modality that has demonstrated early success in treating genetic ocular disorders.
📊
Temel Bulgular & Veri:The approval of voretigene neparavovec-ryzl (tradename Luxturna®), the first single-dose in vivo gene therapy and only on-market treatment for Leber congenital amaurosis Type 2, marked a turning point for inherited retinal diseases.
💡
Sonuç & Katkı:Finally, we discuss trends in gene therapy pricing and approaches in determining the cost effectiveness of single-dose gene therapies for IRDs.
🔬Tür:Deneysel Tarla Denemesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Gene therapy is an emerging therapeutic modality that has demonstrated early success in treating genetic ocular disorders. The approval of voretigene neparavovec-ryzl (tradename Luxturna®), the first single-dose in vivo gene therapy and only on-market treatment for Leber congenital amaurosis Type 2, marked a turning point for inherited retinal diseases. Since then, dozens of in vivo gene therapy products have reached clinical development for other IRDs, including retinitis pigmentosa, achromatopsia, Leber hereditary optical neuropathy , X-linked retinoschisis, and Usher syndrome type 2. This review highlights the clinical and genetic landscape of inherited retinal diseas es targeted by ongoing clinical-stage gene therapy development and outcomes to date for patients treated with voretigene neparvovec. Finally, we discuss trends in gene therapy pricing and approaches in determining the cost effectiveness of single-dose gene therapies for IRDs.

🔖

Bu Makaleye Atıf Yap

DENG, C., BESİRLİ, C. G. (2022). Gene Therapies for Inherited Retinal Diseases. Retina-Vitreus, Cilt: 30 - Sayı: 2, 115–122. https://ajindex.com/articles/589051

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Gottlieb, S. Statement from FDA Commissioner. Published online 2019 Jan 15. Available online: https://www.fda.gov/news- events/press-announcements/statement-fda-commissioner-scott- gottlieb-md-and-peter-marks-md-phd-director-center-biologics. (Accessed on 2 February 2021)
  2. Kaufmann KB, Büning H, Galy A, et al. EMBO Mol Med. 2013 Nov; 5(11): 1642–1661. Published online 2013 Sep 17. doi: 10.1002/emmm.201202287 PMCID: PMC3840483 3. Spark Therapeutics. LUXTURNA (voretigene neparvovec-rzyl) [package insert]. U.S. Food and Drug Administration website. https://www.fda.gov/media/109906/download. Revised 2017. Accessed Jan 18, 2021
  3. Samiy N. Gene therapy for retinal diseases. J Ophthalmic Vis Res. 2014;9(4):506-509. doi:10.4103/2008-322X.150831 5. Cuende N, Rasko JEJ, Koh MBC, et al. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 2018 Nov;20(11):1401-1413. doi: 10.1016/j. jcyt.2018.09.010. Epub 2018 Oct 24. PMID: 30366616
  4. Gao J, Hussain RM, Weng CY. Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence. Clin Ophthalmol. 2020;14:3855-3869. Published 2020 Nov 13. doi:10.2147/OPTH.S231804 7. RetNet. Available online: https://sph.uth.edu/RetNet/. (Accessed on 2 February 2021)
  5. Francis PJ. Genetics of inherited retinal disease. J R Soc Med. 2006;99(4):189-191. doi:10.1258/jrsm.99.4.189 9. Rattner A, Sun H, Nathans J. Molecular genetics of human retinal disease. Annu Rev Genet. 1999;33:89-131. doi: 10.1146/ annurev.genet.33.1.89. PMID: 10690405
  6. Verbakel SK, van Huet RAC, Boon CJF, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018 Sep;66:157- 186. doi: 10.1016/j.preteyeres.2018.03.005. Epub 2018 Mar 27. PMID: 29597005
  7. Tanna P, Strauss RW, Fujinami K, et al. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30. doi:10.1136/ bjophthalmol-2016-308823 12. Zaneveld J, Siddiqui S, Li H, et al. Comprehensive analysis of patients with Stargardt macular dystrophy reveals new genotype- phenotype correlations and unexpected diagnostic revisions. Genet Med. 2015;17(4):262-270. doi:10.1038/gim.2014.174 13. Sikkink SK, Biswas S, Parry NR, et al. X-linked retinoschisis: an update. J Med Genet. 2007;44(4):225-232. doi:10.1136/ jmg.2006.047340 14. Carelli V, Carbonelli M, de Coo IF, et al. International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Ne